Marker Therapeutics, Inc. — Director's Dealing 2017

Sep 25, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TAPIMMUNE INC. (TPIV)
CIK: 0001094038
Period of Report: 2017-09-22

Reporting Person: Hoang Peter L. (Director, CEO and President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-09-22	Common Stock	A	250000	$3.18	Acquired	250000	Direct
2017-09-22	Common Stock	F	70289	$3.18	Disposed	179711	Direct

Footnotes

F1: Represents shares of fully vested restricted stock issued under the Company's 2014 Omnibus Stock Ownership Plan in connection with initial employment as President and Chief Executive Officer and the execution of employment agreement.

F2: Represents withholding of shares of common stock to satisfy tax withholding obligations in connection with the issuance of the restricted stock award.